XML 20 R11.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue Recognition
6 Months Ended
Nov. 30, 2022
Revenue from Contract with Customer [Abstract]  
Revenue Recognition
4. REVENUE RECOGNITION
The Company determines the amount of revenue to be recognized through application of the following steps:
 
   
Identification of the contract with a customer;
 
   
Identification of the performance obligations in the contract;
 
   
Determination of the transaction price;
 
   
Allocation of the transaction price to the performance obligations in the contract; and
 
   
Recognition of revenue when, or as, the Company satisfies the performance obligations.
Essentially all of Neogen’s revenue is generated through contracts with its customers. A performance obligation is a promise in a contract to transfer a product or service to a customer. We generally recognize revenue at a point in time when all of our performance obligations under the terms of a contract are satisfied. Revenue is recognized upon transfer of control of promised products and services in an amount that reflects the consideration we expect to receive in exchange for those products or services. The collectability of consideration on the contract is reasonably assured before revenue is recognized. To the extent that customer payment has been received before all recognition criteria are met, these revenues are initially deferred in other accruals on the balance sheet and the revenue is recognized in the period that all recognition criteria have been met.
Certain agreements with customers include discounts or rebates on the sale of products and services applied retrospectively, such as volume rebates achieved by purchasing a specified purchase threshold of goods and services. We account for these discounts as variable consideration and estimate the likelihood of a customer meeting the threshold in order to determine the transaction price using the most predictive approach. We typically use the most-likely-amount method for incentives that are offered to individual customers, and the expected-value method for programs that are offered to a broad group of customers. Variable consideration reduces the amount of revenue that is recognized. Rebate obligations related to customer incentive programs are recorded in accrued liabilities; the rebate estimates are adjusted at the end of each applicable measurement period based on information currently available.
The performance obligations in Neogen’s contracts are generally satisfied well within one year of contract inception. In such cases, management has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. Management has elected to utilize the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred because the amortization period for the prepaid costs that would otherwise have been deferred and amortized is one year or less. We account for shipping and handling for products as a fulfillment activity when goods are shipped. Shipping and handling costs that are charged to and reimbursed by the customer are recognized as revenues, while the related expenses incurred by Neogen are recorded in sales and marketing expense. Revenue is recognized net of any tax collected from customers; the taxes are subsequently remitted to governmental authorities. Our terms and conditions of sale generally do not provide for returns of product or reperformance of service except in the case of quality or warranty issues. These situations are infrequent; due to immateriality of the amount, warranty claims are recorded in the period incurred.
The Company derives revenue from two primary sources—product revenue and service revenue.
Product revenue consists of shipments of:
 
   
Diagnostic test kits, dehydrated culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation;
 
   
Consumable products marketed to veterinarians, retailers, livestock producers and animal health product distributors; and
 
   
Rodenticides, disinfectants and insecticides to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities.
Revenues for our products are recognized and invoiced when the product is shipped to the customer.
Service revenue consists primarily of:
 
   
Genomic identification and related interpretive bioinformatic services; and
 
   
Other commercial laboratory services.
Revenues for Neogen’s genomics and commercial laboratory services are recognized and invoiced when the applicable laboratory service is performed and the results are conveyed to the customer.
 
Payment terms for products and services are generally 30 to 60 days.
The Company has no contract assets; contract liabilities represent deposits made by customers before the satisfaction of performance obligation(s) and recognition of revenue. Upon completion of the performance obligation(s) that the Company has with the customer, the liability for the customer deposit is relieved and revenue is recognized. These customer deposits are listed as Deferred Revenue on the consolidated balance sheets.
On September 1, 2022, Neogen closed on a Reverse Morris Trust transaction to combine with 3M’s Food Safety business. Similar to Neogen, 3M’s former Food Safety business sells diagnostic test kits, dehydrated culture media, and related products used by food producers and processors to detect foodborne bacteria, allergens and levels of general sanitation. Revenue for these products are recognized and invoiced when the product is shipped to the customer. These products are currently invoiced and distributed by 3M on behalf of Neogen under a number of transition service contracts.
The following table presents disaggregated revenue by major product and service categories for the three and six month periods ended November 30, 2022 and
2021:
 
 
  
Three Months ended November 30,
 
  
Six Months ended November 30,
 
(in thousands)
  
2022
 
  
2021
 
  
2022
 
  
2021
 
Food Safety
  
  
  
  
Natural Toxins, Allergens & Drug Residues
   $ 22,251      $ 21,028      $ 42,038      $ 41,432  
Bacterial & General Sanitation
     41,121        12,252        51,849        23,421  
Culture Media & Other
     82,084        19,935        101,338        37,981  
Rodent Control, Insect Control & Disinfectants
     10,377        8,232        19,952        15,882  
Genomics Services
     5,510        5,685        10,809        11,138  
    
 
 
    
 
 
    
 
 
    
 
 
 
       161,343        67,132        225,986        129,854  
Animal Safety
                                   
Life Sciences
     1,427        1,309        3,016        2,672  
Veterinary Instruments & Disposables
     16,433        15,572        31,106        30,909  
Animal Care & Other
     10,569        10,849        21,095        20,068  
Rodent Control, Insect Control & Disinfectants
     20,665        18,269        42,879        40,418  
Genomics Services
     19,596        17,386        38,300        34,901  
    
 
 
    
 
 
    
 
 
    
 
 
 
       68,690        63,385        136,396        128,968  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total Revenues
   $ 230,033      $ 130,517      $ 362,382      $ 258,822